Clinical Trial Update: Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating dasatinib to prevent oxaliplatin-induced neuropathy in patients with metastatic gastrointestinal cancers receiving FOLFOX with or witho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bile Duct Cancer
• Colorectal Cancer
• Esophageal Cancer
• Gallbladder Cancer
• Gastric Cancer
• Pancreatic Cancer
• Small Bowel Cancer

Drugs mentioned

• Adrucil (5-fluorouracil)
• Avastin (bevacizumab)
• Eloxatin (oxaliplatin)
• Sprycel (dasatinib)
• Wellcovorin (leucovorin calcium)

Snippet

Sponsor: Anne Noonan | Conditions: Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma | Phase 1 | Status: COMPLETED